Teva: Laquinimod reduces brain damage in MS patients
Teva CSO: Laquinimod might also help treat Crohn’s disease, lupus nephritis, Huntington’s disease and Alzheimer’s. Teva Pharmaceutical Industries Ltd. and Active…
Novartis Confirms Long Term Benefits Of Gilenya In Multiple Sclerosis
9/25/2013 1:36 AM ET Novartis International AG (NVS: Quote) announced that new data showing the benefits of Gilenya on patient outcomes…
Stuart Schlossman
REGISTER to listen to a Live Webcast of our 2013 MS Symposium
LIVE – This Coming Saturday – September 28th For the many over the last couple of years, who have wanted…
Stuart Schlossman
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio(R) (teriflunomide)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–August 30, 2013– Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the European Commission…
Stuart Schlossman
Explore how to start a conversation with your doctor about Tecfidera
Explore how to start a conversation with your doctor about Tecfidera Tecfidera (dimethyl fumarate) is a prescription medicine used to treat…
Stuart Schlossman
One Day for everyday – An Aubagio – MS Orla Medication – Learning program by Lake Buena Vista, Fl on Sept 7th, 2013
MS Views and News™ Disclaimer As a service and courtesy to you, the MS Views and News (MSVN) organization…
Stuart Schlossman
FDA Warns of PML Case With Gilenya
Published: Aug 29, 2013 By John Gever, Deputy Managing Editor, MedPage Today SILVER SPRING, Md. — A patient being treated for…
Stuart Schlossman
Patient taking Novartis MS pill developed rare disease
Tue Jul 30, 2013 * Patient took Novartis’ Gilenya MS pill * Developed progressive viral disease * First incidence in…
Stuart Schlossman
GUIDE TO STAYING ON TRACK WITH AUBAGIO® (teriflunomide)
1KEEP UP WITH YOUR ONCE-DAILY PILL AND YOUR FIRST 6 MONTHS OF MONTHLY MONITORING Once you’ve been prescribed AUBAGIO it’s…
Stuart Schlossman
Research and Markets: Laquinimod (Multiple Sclerosis) – Forecast and Market Analysis to 2022
SummaryGlobalData has released its new PharmaPoint Drug Evaluation report, “Laquinimod (Multiple Sclerosis) – Forecast and Market Analysis to 2022”. Multiple…
Stuart Schlossman
